SCHEMBL4105454

SCHEMBL4105454

N[C@@H](CO)CCC(=O)NCCC1C(Nc2nccc(N3CCCCCC3)n2)CCCN1C1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.39
▸ HRH4 Q9H3N8 6/20 0.35
▸ CCNK O75909 1/20 0.34
▸ CDK12 Q9NYV4 1/20 0.34
▸ ROCK2 O75116 1/20 0.33
▸ ALK Q9UM73 5/20 0.33
▸ ACACB O00763 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CCR4 P51679 1/20 0.32
▸ MRGPRX1 Q96LB2 1/20 0.32
▸ IGF1R P08069 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116340 1.00 CXCR4 (0.39) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL4111561 0.93 CXCR4 (0.39) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL4115415 0.93 CXCR4 (0.39) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL4110044 0.88 CXCR4 (0.40) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL4116258 0.88 CXCR4 (0.40) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL13696580 0.87 CXCR4 (0.39) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL2006649 0.87 CXCR4 (0.39) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL4111574 0.87 CXCR4 (0.39) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL4115339 0.86 CXCR4 (0.45) CXCR4HRH4CCNKCDK12ROCK2
SCHEMBL4122202 0.85 CXCR4 (0.38) CXCR4HRH4CCNKCDK12ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
EP-1852432-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 CXCR4 1/4885HRH4 152/4885CCNK 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback